MedTrace Logo

Improving Fibrosis Outcomes With Metformin

NCT02306070 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2018-04-17

No results posted yet for this study

Summary

This study will evaluate the role of Metformin on liver fibrosis in HCV-HIV co-infected and HCV mono-infected patients with insulin resistance receiving DAA HCV treatment.

Conditions

  • HIV Infection
  • Hepatitis C

Interventions

DRUG

Metformin

metformin treatment + standard of care dietary and exercise advice

DRUG

No metformin treatment

no metformin treatment + standard of care dietary and exercise advice

Sponsors & Collaborators

  • CIHR Canadian HIV Trials Network

    collaborator NETWORK

  • Ottawa Hospital Research Institute

    lead OTHER

Principal Investigators

  • Curtis Cooper, MD · The Ottawa Hospital Division of Infectious Diseases

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-31
Primary Completion
2017-09-30
Completion
2018-04-03

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02306070 on ClinicalTrials.gov